OncoMatch/Clinical Trials/NCT07357519

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Is NCT07357519 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LNTH2403 Phase 1 dose and Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). for relapsed / refractory osteosarcoma.

Phase 1/2RecruitingLantheus Medical ImagingNCT07357519Data as of May 2026

Treatment: LNTH2403 Phase 1 dose · Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). — This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.

Check if I qualify

Extracted eligibility criteria

Cancer type

Osteosarcoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: chemotherapy — neoadjuvant / perioperative systemic therapy included

Progression following at least one course of chemotherapy, which includes neoadjuvant / perioperative systemic therapy.

Lab requirements

Blood counts

Kidney function

Liver function

Organ Function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

UCLA · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify